JP2025511145A - Ｘ８４２製剤 - Google Patents
Ｘ８４２製剤 Download PDFInfo
- Publication number
- JP2025511145A JP2025511145A JP2024557950A JP2024557950A JP2025511145A JP 2025511145 A JP2025511145 A JP 2025511145A JP 2024557950 A JP2024557950 A JP 2024557950A JP 2024557950 A JP2024557950 A JP 2024557950A JP 2025511145 A JP2025511145 A JP 2025511145A
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- pharmaceutical formulation
- carrier
- tablet
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/084214 WO2023184282A1 (en) | 2022-03-30 | 2022-03-30 | X842 formulation |
| CNPCT/CN2022/084214 | 2022-03-30 | ||
| PCT/CN2023/083375 WO2023185624A1 (en) | 2022-03-30 | 2023-03-23 | X842 formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511145A true JP2025511145A (ja) | 2025-04-15 |
| JP2025511145A5 JP2025511145A5 (https=) | 2026-04-08 |
Family
ID=81386826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557950A Pending JP2025511145A (ja) | 2022-03-30 | 2023-03-23 | Ｘ８４２製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4499046A1 (https=) |
| JP (1) | JP2025511145A (https=) |
| KR (1) | KR20240165457A (https=) |
| CN (2) | CN119139298A (https=) |
| AU (1) | AU2023247528A1 (https=) |
| MX (1) | MX2024011716A (https=) |
| WO (2) | WO2023184282A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260019468A (ko) * | 2023-05-08 | 2026-02-10 | 싱클루스 파마 홀딩 에이비 (피유비엘) | 위식도 역류 질환(gerd) 치료를 위한 리나프라잔 글루레이트 |
| WO2026032974A1 (en) | 2024-08-05 | 2026-02-12 | Cinclus Pharma Holding AB (publ) | Formulation of linaprazan glurate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004518709A (ja) * | 2001-02-13 | 2004-06-24 | アストラゼネカ・アクチエボラーグ | 新規放出修飾製剤 |
| US20050249799A1 (en) * | 2004-03-03 | 2005-11-10 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
| CN101513403A (zh) * | 2008-02-21 | 2009-08-26 | 上海慧德医药科技有限公司 | 含有苯并咪唑类化合物的药物制剂 |
| FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
| CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
| CN106279151A (zh) * | 2015-06-26 | 2017-01-04 | 江苏太瑞生诺生物医药科技有限公司 | 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法 |
| WO2018026764A1 (en) * | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
| WO2020101860A1 (en) | 2018-11-16 | 2020-05-22 | Cnh Industrial America Llc | System and method for aligning arms of an agricultural header |
| CN114901262A (zh) * | 2019-11-04 | 2022-08-12 | 辛克鲁斯制药控股有限公司 | X842的口服制剂 |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| US20220002297A1 (en) | 2020-07-02 | 2022-01-06 | Cinclus Pharma Ag | Polymorphs of x842 |
-
2022
- 2022-03-30 WO PCT/CN2022/084214 patent/WO2023184282A1/en not_active Ceased
-
2023
- 2023-03-23 JP JP2024557950A patent/JP2025511145A/ja active Pending
- 2023-03-23 CN CN202411410163.7A patent/CN119139298A/zh active Pending
- 2023-03-23 EP EP23719627.4A patent/EP4499046A1/en active Pending
- 2023-03-23 WO PCT/CN2023/083375 patent/WO2023185624A1/en not_active Ceased
- 2023-03-23 CN CN202380010889.9A patent/CN117157059B/zh active Active
- 2023-03-23 AU AU2023247528A patent/AU2023247528A1/en active Pending
- 2023-03-23 KR KR1020247035992A patent/KR20240165457A/ko active Pending
-
2024
- 2024-09-24 MX MX2024011716A patent/MX2024011716A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023247528A1 (en) | 2024-09-26 |
| WO2023184282A1 (en) | 2023-10-05 |
| CN119139298A (zh) | 2024-12-17 |
| EP4499046A1 (en) | 2025-02-05 |
| CN117157059B (zh) | 2024-09-13 |
| WO2023185624A1 (en) | 2023-10-05 |
| MX2024011716A (es) | 2024-11-08 |
| KR20240165457A (ko) | 2024-11-22 |
| CN117157059A (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4780522B2 (ja) | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 | |
| TWI673051B (zh) | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 | |
| CN102316867B (zh) | 氨氯地平微球制剂、其制备方法及应用 | |
| CN101636152A (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| BRPI0712865B1 (pt) | Composição farmacêutica estabilizada compreendendo fesoterodina, método para preparação da mesma e uso de uma substância | |
| JP4977611B2 (ja) | 新規な種類の界面活性剤様物質 | |
| JP2025511145A (ja) | Ｘ８４２製剤 | |
| TW200848056A (en) | Solid dispersion of a neurokinin antagonist | |
| CN111514142B (zh) | 含硝羟喹啉前药的药物组合物及其制备方法和应用 | |
| KR20230155504A (ko) | (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를 포함하는 제약 투여 형태 | |
| JP2003534296A (ja) | 溶出性の改善されたプランルカスト固体分散系及びその製造方法 | |
| KR100209201B1 (ko) | 1,4-디히드로피리딘 유도체를 함유하는 고체 분산 정제 및 그의 제조방법 | |
| US11285152B2 (en) | Stable oral pharmaceutical composition of imatinib | |
| JPWO2013172297A1 (ja) | ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤 | |
| KR20140050876A (ko) | 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도 | |
| EP3881832A1 (en) | Pharmaceutical composition containing tamsulosin hydrochloride with excellent acid resistance and preparation method therefor | |
| CN113950324A (zh) | 微型软胶囊萘普生组合物 | |
| HK40102489B (zh) | X842制剂 | |
| HK40102489A (zh) | X842制剂 | |
| JP7817367B2 (ja) | 難溶性薬物の浸透圧ポンプ制御放出錠剤及びその製造方法 | |
| BR112024019689B1 (pt) | Formulação farmacêutica para administração oral, dispersão sólida, e, comprimido ou cápsula | |
| JP7058104B2 (ja) | アプレピタントを有効成分とする医薬錠剤 | |
| CN107249569A (zh) | 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂 | |
| KR100539706B1 (ko) | 타크로리무스 및 장용성 고분자를 함유하는 고체분산체 | |
| CN103054806A (zh) | 一种阿维莫泮固体分散体及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260319 |